A combination antibody treatment for Covid-19 has met its primary endpoint of improving survival in patients hospitalised with the disease, the developer Regeneron Pharmaceuticals Inc announced on 16 June. The treatment, REGEN-COV, is a combination of the monoclonal antibodies casirivimab and imdevimab, which are both investigational compounds. The US Food and Drug Administration has given the combination treatment an emergency use authorisation.
